Artelo Biosciences' ART26.12 Shows Promise in Spinal Cord Injury Pain Study
Event summary
- Artelo Biosciences presented preclinical data showing ART26.12 reduced neuropathic pain in a spinal cord injury mouse model.
- The study demonstrated decreased mechanical hypersensitivity, spontaneous pain behaviors, and nociceptor hyperexcitability.
- ART26.12 is currently in Phase 1 development as a non-opioid analgesic for chronic pain conditions.
- Nearly 90% of spinal cord injury patients experience chronic pain, with up to 60% suffering from neuropathic pain.
The big picture
Artelo Biosciences' positive preclinical data for ART26.12 in spinal cord injury-related neuropathic pain highlights the growing interest in non-opioid alternatives for chronic pain management. The study results reinforce the potential of FABP5 inhibition as a novel therapeutic strategy, positioning Artelo to compete in a market with significant unmet needs and limited effective treatments.
What we're watching
- Clinical Translation
- How preclinical results will translate to human studies in Phase 1 development.
- Market Differentiation
- Whether ART26.12 can establish itself as a first-in-class non-opioid analgesic for chronic pain.
- Indication Expansion
- The pace at which Artelo will explore additional pain conditions beyond chemotherapy-induced peripheral neuropathy.